{"id":3562,"date":"2025-06-02T08:54:11","date_gmt":"2025-06-02T06:54:11","guid":{"rendered":"https:\/\/remeds.org\/?p=3562"},"modified":"2025-11-14T09:26:07","modified_gmt":"2025-11-14T08:26:07","slug":"umass-licenses-sirna-mecp2-duplication-syndrome","status":"publish","type":"post","link":"https:\/\/remeds.org\/es\/2025\/06\/02\/umass-licenses-sirna-mecp2-duplication-syndrome\/","title":{"rendered":"Un nuevo paso adelante en la b\u00fasqueda de una cura: UMass Chan licencia tecnolog\u00eda de ARNip \u00a0"},"content":{"rendered":"<p>La Facultad de Medicina UMass Chan ha licenciado una prometedora tecnolog\u00eda basada en ARNip a M2DS, una empresa emergente dedicada a avanzar la tecnolog\u00eda como tratamiento para el s\u00edndrome de duplicaci\u00f3n MECP2. Esto marca un gran paso adelante en la traducci\u00f3n de investigaci\u00f3n de vanguardia a la realidad cl\u00ednica.<a href=\"https:\/\/dupmecp2.eu\/recruitement-hero\/\"><\/a><\/p>\n\n\n\n<p>La tecnolog\u00eda fue desarrollada en el laboratorio de la Dra. Khvorova, con el proyecto liderado por Vignesh Hariharan. La investigaci\u00f3n inicial se realiz\u00f3 gracias a la financiaci\u00f3n de Cure MDS y el Rett Syndrome Research Trust. Este ARNip funciona dirigi\u00e9ndose y degradando el ARN mensajero responsable de la sobreproducci\u00f3n de la prote\u00edna MeCP2. <\/p>\n\n\n\n<p>En estudios con ratones, una dosis lleg\u00f3 al cerebro y la m\u00e9dula espinal de manera efectiva y podr\u00eda requerir solo una o dos administraciones al a\u00f1o. Al licenciar esta tecnolog\u00eda a M2DS, la terapia ahora entra en un camino donde puede recibir el apoyo necesario para avanzar hacia ensayos en humanos. <\/p>\n\n\n\n<p>Adem\u00e1s de los ensayos cl\u00ednicos en curso de Ionis y HuidaGene, este hito puede a\u00f1adir una adici\u00f3n prometedora a la cartera de posibles tratamientos para este trastorno raro y complejo.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/bridge.umassmed.edu\/s\/news\/news-article\/umass-chan-licenses-sirna-therapeutics-for-mecp2-duplication-syndrome-MCMWKNCJYQ25CQHF5YITTOM757HU\">Ver comunicado de prensa<\/a><\/p>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>UMass Chan Medical School has licensed a promising siRNA-based technology to M2DS, a startup company dedicated to advancing the technology as a treatment for MECP2 Duplication Syndrome. This marks a major step forward in translating cutting-edge research into clinical reality. The technology was developed in the lab of Dr. Khvorova, with the project led by [&hellip;]<\/p>\n","protected":false},"author":114,"featured_media":3563,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jf_save_progress":"","footnotes":""},"categories":[9,24],"tags":[],"class_list":["post-3562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","category-sirna"],"_links":{"self":[{"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/posts\/3562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/users\/114"}],"replies":[{"embeddable":true,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/comments?post=3562"}],"version-history":[{"count":3,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/posts\/3562\/revisions"}],"predecessor-version":[{"id":3567,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/posts\/3562\/revisions\/3567"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/media\/3563"}],"wp:attachment":[{"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/media?parent=3562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/categories?post=3562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/remeds.org\/es\/wp-json\/wp\/v2\/tags?post=3562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}